Is Simtriyo (centanafadine) appropriate for a patient with bipolar I disorder, ADHD, anxiety, and depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Simtriyo (Centanafadine) Should NOT Be Used in Patients with Bipolar I Disorder

Centanafadine is contraindicated in this patient with bipolar I disorder because stimulant-like medications and monoamine reuptake inhibitors can destabilize mood and precipitate manic episodes. While centanafadine is FDA-approved for ADHD treatment 1, the presence of bipolar I disorder represents a critical safety concern that supersedes its ADHD indication.

Why This Patient Cannot Use Centanafadine

Mechanism-Based Risk

Centanafadine is a triple monoamine reuptake inhibitor (norepinephrine > dopamine > serotonin) 1. This mechanism poses significant risk in bipolar disorder:

  • Mood destabilization: Medications that enhance dopaminergic and noradrenergic transmission can trigger manic episodes or mixed states 2
  • Similar to antidepressants: Guidelines explicitly warn that antidepressants (which also increase monoamines) may destabilize mood or incite mania in bipolar patients 2
  • Substance-induced mania: A manic episode precipitated by such agents is characterized as substance-induced per DSM criteria 2

Guideline-Based Contraindication

The established treatment algorithm for bipolar disorder with comorbid ADHD is clear and sequential 2:

  1. First: Stabilize bipolar symptoms with mood stabilizers (lithium, valproate) or atypical antipsychotics 2
  2. Second: Once mood is adequately controlled for 12-24 months, ADHD medications may be considered 2
  3. Third: Even then, stimulants should only be added while maintaining the mood stabilizer 2

This patient's bipolar disorder must be treated and stabilized BEFORE any ADHD medication is introduced.

The Correct Treatment Sequence

Phase 1: Stabilize Bipolar Disorder (Priority)

Start with FDA-approved mood stabilizers 2:

  • Lithium (FDA-approved for ages 12+) 2
  • Valproate (divalproex) 2
  • Atypical antipsychotics: aripiprazole, risperidone, quetiapine, olanzapine 2

For comorbid depression/anxiety in bipolar disorder:

  • SSRIs may be used only in combination with a mood stabilizer 2, 3
  • Never use antidepressants as monotherapy 2, 3

Phase 2: Address ADHD (Only After Mood Stabilization)

Once bipolar symptoms are controlled for 12-24 months 2:

  • Low-dose mixed amphetamine salts have demonstrated safety when added to divalproex in stabilized bipolar patients 2
  • Non-stimulants (atomoxetine, guanfacine, clonidine) may be safer alternatives given lower mood destabilization risk 4
  • Maintain the mood stabilizer throughout ADHD treatment 2

Critical Pitfalls to Avoid

  1. Never treat ADHD first in bipolar disorder: The risk of precipitating mania outweighs ADHD symptom relief
  2. Never use monoamine-enhancing agents without mood stabilizer coverage: This includes centanafadine, stimulants, and antidepressants
  3. Don't assume "non-stimulant" means safe in bipolar disorder: Centanafadine's triple reuptake inhibition mechanism carries similar risks to stimulants despite its non-stimulant classification
  4. Monitor for mood destabilization: Even with proper sequencing, any ADHD medication can unmask or worsen bipolar symptoms 2

Addressing the Anxiety and Depression

The patient's anxiety and depression likely represent:

  • Bipolar depression (requires mood stabilizer ± SSRI) 3
  • Comorbid anxiety (may improve with mood stabilization) 2

These symptoms should be managed within the bipolar treatment framework, not as separate conditions requiring additional monoaminergic agents.

Bottom Line

Centanafadine is inappropriate for this patient until bipolar I disorder is stabilized with appropriate mood stabilizers for at least 12-24 months. The priority is preventing manic episodes and maintaining mood stability, which directly impacts morbidity, mortality (suicide risk in bipolar disorder), and quality of life. Only after achieving sustained mood stability should ADHD treatment be cautiously introduced while maintaining mood stabilizer therapy 2.

References

1
Research

Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD).

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026

2
Guideline

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

Related Questions

What are the recommended dosing, efficacy, safety profile, and monitoring guidelines for centanafadine in treating ADHD in children, adolescents, and adults?
What is Simtryo (centanafadine) and how is it indicated for ADHD treatment?
How does the newest ADHD medication, Simtriyo (centanafadine), work?
Is centanafadine (Simtriyo) FDA‑approved for treating ADHD in children aged 6 to 12 years?
What is the most appropriate mood stabilizer for a patient with bipolar disorder who is taking lisdexamfetamine (Vyvanse)?
How should a 79-year-old female patient with new-onset right lower quadrant pain radiating to the umbilicus, soreness, no nausea, vomiting, or diarrhea, and regular bowel movements be evaluated and managed?
What additional work‑up is indicated for a patient whose platelet count increased from 540 × 10⁹/L to 707 × 10⁹/L while the complete blood count, peripheral smear, comprehensive metabolic panel, and thyroid‑stimulating hormone level are otherwise normal?
Can trazodone be used to treat temporomandibular joint (TMJ) disorder?
What is the appropriate evaluation and management for a patient with an elevated free testosterone of 315.4 (units) and otherwise normal laboratory results?
What is the recommended antiviral prophylaxis guideline for a patient with strong hepatitis B core antibody positivity who is initiating ixekizumab (TALTZ) for psoriasis?
How should I evaluate and manage a patient with bilateral jaw pain that began a few days ago?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.